What is Biosynthetic Technologies?
Biosynthetic Technologies is a pioneer in the manufacturing of sustainable base oils derived from organic fatty acids. Their core innovation, Estolides, represents a breakthrough in biobased synthetic chemistry, offering a drop-in solution that is fully compatible with existing lubricant formulations. This technical advantage allows the company to serve a diverse client base, ranging from industrial lubricant manufacturers to personal care product developers, without requiring significant infrastructure changes from their partners. By prioritizing environmental sustainability alongside technical efficacy, the company has carved out a unique niche in the specialty chemicals market, effectively bridging the gap between traditional petroleum-based products and the next generation of eco-friendly industrial fluids.
How much funding has Biosynthetic Technologies raised?
Biosynthetic Technologies has raised a total of $52.2M across 4 funding rounds:
Unspecified
$14.7M
Unspecified
$9M
Private Equity
$12M
Debt
$16.5M
Unspecified (2012): $14.7M, investors not publicly disclosed
Unspecified (2013): $9M, investors not publicly disclosed
Private Equity (2014): $12M supported by Evonik
Debt (2016): $16.5M, investors not publicly disclosed
Key Investors in Biosynthetic Technologies
Evonik
Evonik Industries AG is a global leader in specialty chemicals, focusing on resource efficiency and performance materials to drive sustainable industrial innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Biosynthetic Technologies?
With the recent influx of capital, Biosynthetic Technologies is well-positioned to accelerate its market penetration and expand its manufacturing capacity. The strategic focus will likely shift toward optimizing supply chain efficiencies and deepening partnerships within the global metalworking and industrial sectors. As regulatory pressures mount for industries to reduce their carbon footprint, the company's ability to provide high-performance, biobased alternatives will be a critical driver of its future growth. Investors and industry analysts will be monitoring the firm's ability to scale its Estolide production while maintaining the cost-competitiveness necessary to displace legacy synthetic lubricants in high-volume applications.
See full Biosynthetic Technologies company page
